missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ p14ARF Polyclonal Antibody
Rabbit Polyclonal Antibody
$803.38
Specifications
| Antigen | p14ARF |
|---|---|
| Content And Storage | -20°C, Avoid Freeze/Thaw Cycles |
| Applications | Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry |
| Classification | Polyclonal |
| Conjugate | Unconjugated |
| Catalog Number | Mfr. No. | Quantity | Price | Quantity & Availability | |||||
|---|---|---|---|---|---|---|---|---|---|
| Catalog Number | Mfr. No. | Quantity | Price | Quantity & Availability | |||||
|
PIPA532529
|
Invitrogen™
PA532529 |
500 μL |
Each for $803.38
|
|
|||||
Description
Heat-mediated antigen retrieval is recommended prior to staining, using a 10mM citrate buffer, pH 6.0, for 10 minutes followed by cooling at room temperature for 20 min. Following antigen retrieval, incubate samples with primary antibody for 30 min at room temperature. A suggested positive control is lymphoma.
The INK4a locus on chromosome 9p21 is frequently affected in human tumors. It encodes two structurally distinct tumor suppressor proteins, p16INK4a and the alternative reading frame protein, ARF (p14ARF in human and P19ARF in mouse). These two proteins interact with the upstream proteins: retinoblastoma protein and p53 tumor suppressors, respectively. Each of these proteins has a role in the senescence of primary cells, activates pathways for cell cycle control and tumor suppression. The p14ARF (or P19ARF in mouse) proteins can induce both G1 and G2 phase arrest in a manner that depends on functional p53. The mouse and human ARF proteins have different functions in tumor suppression; this distinction may contribute to the different levels of tumor proneness of these species.Specifications
| p14ARF | |
| Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
| Unconjugated | |
| Rabbit | |
| RUO | |
| PBS with 1% BSA and 0.1% sodium azide; pH 7.6 | |
| P42771 | |
| 1029 | |
| Synthetic peptide derived from C-terminus of human p14. | |
| Antibody |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Polyclonal | |
| Liquid | |
| IgG | |
| Human | |
| CDKN2A | |
| Alternative reading frame; ARF; ARF-INK4a; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; CDKN2A; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; p14 p16; P14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; P16INK4A; P16-INK4A; P19; P19 TP16; p19>ARF>; P19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF | |
| CDKN2A | |
| Primary | |
| Antigen affinity chromatography |